325 related articles for article (PubMed ID: 29313444)
1. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
5. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
6. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
7. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
8. [Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].
Yoshida H; Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):193-7. PubMed ID: 27093730
[No Abstract] [Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
10. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
11. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
13. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
14. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
Graybill WS; Pothuri B; Chase DM; Monk BJ
Gynecol Oncol; 2017 Jul; 146(1):11-15. PubMed ID: 28392129
[No Abstract] [Full Text] [Related]
16. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition as frontline therapy in ovarian cancer.
Moore KN; Pothuri B; Monk B; Coleman RL
Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
[TBL] [Abstract][Full Text] [Related]
18. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
